Pseudofolliculitis Barbae Clinical Trial
Official title:
Clinical Safety and Efficacy of Prototype Devices for Hair Growth Control: Task 2.4
To report the safety and efficacy of 1064nm low fluence laser hair reduction for the treatment of pseudofolliculitis barbae
Pseudofolliculitis barbae (PFB) is an acneiform eruption of the bearded area usually seen in
dark-skinned individuals with thick, tightly curled hair. Typically, the hair shafts curve
back directly into adjacent skin or the shaft penetrates through the follicular epithelium
into the superficial dermis. The subsequent foreign body inflammatory reaction leads to
discomfort, pigment alteration, infection, scarring and a potential decreased ability to
shave. PFB continues to be a significant problem in the military with tremendous cost to the
US Government, both in direct treatment of the condition as well as indirectly due to the
loss of man-hours in personnel training, clinic visits, and ultimately, administrative
separation.
Chemical depilatories, topical corticosteroids, topical retinoids, topical antibiotics, and
eflornithine hydrochloride cream are helpful in the management of PFB. Growing a beard is
usually curative; however in the military a clean shaven face is required. Since 1984, the
US Navy has not allowed the wearing of beards, noting that facial hair may interfere with
the proper fitting of protective gear used against biochemical warfare agents, or in the
case of oxygen mask or breathing apparatus. In refractory cases, permanent laser hair
removal with the long-pulse Nd:YAG has been shown to decrease the severity of PFB in dark
skinned individuals. This wavelength is safe, effective, and due to its increased
penetration, allows for increased ratio of hair bulb to epidermal heating in patients with
Fitzpatrick skin type IV through VI.
Traditional 1064nm laser fluences (defined here as 22-40 J/cm2) for a normal bearded subject
produce significant discomfort. Blistering and subsequent pigmentary changes have been
reported in patients with type V-VI skin.7 Patients often require topical anesthesia with
prolonged application times, ranging from 45 to 90 minutes. Treatments are usually scheduled
every four to six weeks and in the military, these are conducted by trained physicians at
major treatment facilities. Theoretically, the aim of the 1064nm laser treatment is long
lasting or permanent hair reduction via conductive thermal diffusion causing lethal damage
to the hair bulb and bulge area from the melanosome-containing hair shaft and matrix.
However, in patients treated at the highest possible fluence eventually become symptomatic
within 12 to 18 months of their final treatment.
The purpose of this study was to determine if PFB could be mitigated with a weekly treatment
protocol. We evaluated a1064nm Nd:YAG laser using a fluence of 12J/cm2 in patients with PFB
and Fitzpatrick skin types IV, V and VI.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04403282 -
Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial
|
Phase 4 | |
Active, not recruiting |
NCT03569956 -
Shaving Satisfaction in Males With Skin Irritation From Shaving
|
N/A | |
Completed |
NCT04993066 -
Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus
|
N/A | |
Completed |
NCT03043534 -
Pre-Shave Gel and Brush in Pseudofolliculitis Barbae
|
N/A | |
Completed |
NCT00176995 -
Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae
|
Phase 2 | |
Withdrawn |
NCT04220502 -
Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae
|
Early Phase 1 |